AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin.
"Partial correction of anemia by erythropoietin improves hemodialysis (HD)-associated immunosuppression. It is not known whether hemoglobin normalization improves immune status further. The authors prospectively compared the immune function of HD patients with congestive heart failure or ischemic heart disease on erythropoietin therapy randomized to normal versus anemic blood hemoglobin concentration," researchers in the United States report.
"HD patients were randomized into a normal hemoglobin group (n=17, target hemoglobin of 14[+ or -]1 g/dL) or an anemic hemoglobin group (n=18, target hemoglobin 10[+ or -]1 g/dL)," said Renato M. B. Roman and collaborators at the University of Virginia and Amgen, Inc. "Delayed-type hypersensitivity, CD4 and CD8 counts, anti-tetanus toxoid antibody levels, erythrocyte complement receptor 1 expression, and lymphocyte proliferative responsiveness were measured. The observation period was 1 year, and the trial was open label. Target hemoglobin was achieved and maintained in both groups."
"Significantly improved cutaneous reactivity was seen in the normal hemoglobin group (p=0.003)," reported the investigators. "The prevalence of anergy decreased in the normal hemoglobin group (from 60 to 20%) but increased in the anemic hemoglobin group (from 57 to 86%). The anemic hemoglobin group had higher CD8 counts compared with baseline (p=0.0001) and compared with the normal hemoglobin group (p=0.038). Both groups had significant ...